Q1 2021 Xvivo Perfusion AB Earnings Call Transcript
Ladies and gentlemen, welcome to the Xvivo Group interim report Q1 2021. (Operator Instructions) I will now hand it over to CEO, Dag Andersson. Please go ahead with your meeting.
()-&
Thank you very much for the introduction. So dear all, welcome to the first quarterly telephone conference 2021. And I am happy to present to you, together with my CFO, Kristoffer Nordstrom.
And as mentioned in the quarterly report released this morning, the year has started well for XVIVO and quarter 1 was positive from many different aspects. And both sales margins, EBITDA showed positive performance or very positive performance, sales up 38% in the quarter. We had a gross margin of 75%, and EBITDA margin adjusted of 11%. And also worth mentioning strong organic growth of 10%.
And particularly positive was the development of thoracic machine perfusion sales, which increased by 45% versus same quarter last year. This is actually an outstanding number, bearing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |